ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
IMGN 2.88 +0.38(15.20%)
Will IMGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IMGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMGN
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
IMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?